The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy
Open accessAbstract
Women with BRCA1 and BRCA2 mutations have an elevated risk of breast cancer and ovarian cancer, but also of developing second primary breast cancer. BRCA1/2 mutation carriers with breast cancer must choose between breast conservation (BCT) and mastectomy (M) yet data on outcomes are limited. The purpose of this study is to compare long-term outcome following BCT and M in BRCA1/2 carriers. 655 women with BRCA1/2 mutations diagnosed with breast cancer and treated with BCT (n = 302) or M (n = 353) were identified and underwent follow-up to assess local, regional, and systemic recurrence. Local failure as first failure was significantly more likely in those treated with BCT compared to M, with a cumulative estimated risk of 23.5 vs. 5.5%, respectively, at 15 years (P < 0.0001); 15-year estimates in carriers treated with BCT and chemotherapy was 11.9% (P = 0.08 when compared to M). Most events appeared to be second primary cancers rather than failure to control the primary tumor. The risk of contralateral breast cancer was high in all groups, exceeding 40%, but was not statistically significantly different by use of adjuvant radiotherapy (RT) or not, suggesting no added risk from scatter RT at 10 and 15 years. There were no differences seen in regional or systemic recurrences between the BCT and M groups, and no difference in overall survival. In conclusion, BRCA1/2 mutation carriers with breast cancer have similar survival whether treated with M or BCT. However, women undergoing BCT have an elevated risk of a second in-breast event that is significantly reduced in the presence of chemotherapy. Contralateral breast cancer events are very common.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., Jeong, J.-H., & Wolmark, N. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa022152 · Cited by 6,249
Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., Aguilar, M., & Marubini, E. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020989 · Cited by 4,450
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07065-7 · Cited by 452
Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status
Haffty, B. G., Harrold, E., Khan, A. J., Pathare, P., Smith, T. E., Turner, B. C., Glazer, P. M., Ward, B., Carter, D., Matloff, E., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08434-9 · Cited by 307
Self-citationKirova, Y. M., Stoppa-Lyonnet, D., Savignoni, A., Sigal-Zafrani, B., Fabre, N., & Fourquet, A. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.037 · Cited by 129
Breast-Conserving Surgery in BRCA1/2 Mutation Carriers: Are We Approaching an Answer?
Garcia-Etienne, C. A., Barile, M., Gentilini, O. D., Botteri, E., Rotmensz, N., Sagona, A., Farante, G., Galimberti, V., Luini, A., Veronesi, P., et al. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0638-7 · Cited by 100
Familial breast cancer: an investigation into the outcome of treatment for early stage disease
Eccles, D., Simmonds, P., Goddard, J., Coultas, M., Hodgson, S., Lalloo, F., Evans, G., & Haites, N. (2001) · Familial Cancer · doi:10.1023/a:1013867917101 · Cited by 53
Research works printed but not linked: 19
- Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408 · DOI · Paper page
- Begg CB, Haile R, Borg A et al (2008) Variation of breast cancer risk amond BRCA1/2 carriers. JAMA 299:194–201
- Mann GJ, Thorne H, Balleine RM et al (2006) Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 8:R12 · DOI
- Phillips KA, Milne RL, Buys S et al (2005) Agreement between self-reported breast cancer treatment and medical records in a population-based breast cancer family registry. J Clin Oncol 23:4679–4686 · DOI
- Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481 · DOI · Paper page
- Gooley TA, Leisenring W, Crowley J et al (1999) Estimation of failure probabilities in the presence of competing risks: new representation of old estimators. Stat Med 18:695–706 · DOI · Paper page
- Pepe M (1991) Inference for events with dependent risks in multiple endpoints studies. J Am Stat Assoc 86:770–778 · DOI · Paper page
- Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 366:2087–2106 · DOI · Paper page
- Schwartz GF, Veronesi U, Clough KB, et al (2006) In: Proceedings on the consensus conference on breast conservation, April 28 to May 2, 2005, Milan, Italy. Cancer 107:242–250 · doi:10.1002/cncr.21988
- Turner BC, Harrold E, Matloff E et al (1999) BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol 17:3017–3024 · DOI
- Donegan WL, Perez-Mesa CM, Watson FR (1966) A biostatistical study of locally recurrent breast carcinoma. Surg Gynecol Obstet 122:529–540
- Anderson SJ, Wapnir I, Dignam JJ et al (2009) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol 27:2466–2473 · DOI · Paper page
- Wapnir IL, Anderson SJ, Mamounas EP et al (2006) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 24:2028–2037 · DOI · Paper page
- Fourquet A, Stoppa-Lyonnet D, Kirova YM et al (2009) Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status. Am J Clin Oncol 32:127–131 · DOI
- Kauff ND, Domchek SM, Friebel TM et al (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter prospective study. J Clin Oncol 26:1331–1337 · DOI · Paper page
- King MC, Wieand S, Hale K et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286:2251–2256 · DOI · Paper page
- Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718–1729 · DOI · Paper page
- Pierce LJ, Levin AM, Rebbeck TR et al (2006) Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24:2437–2443 · DOI · Paper page
- Robson M, Levin D, Federici M et al (1999) Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 91:2112–2117 · DOI · Paper page
Cited by
Kaufmann, M., von Minckwitz, G., Mamounas, E. P., Cameron, D., Carey, L. A., Cristofanilli, M., Denkert, C., Eiermann, W., Gnant, M., Harris, J. R., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2108-2 · Cited by 482
Tung, N. M., Boughey, J. C., Pierce, L. J., Robson, M. E., Bedrosian, I., Dietz, J. R., Dragun, A., Gelpi, J. B., Hofstatter, E. W., Isaacs, C. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00299 · Cited by 332
Self-citationvan den Broek, A. J., van ’t Veer, L. J., Hooning, M. J., Cornelissen, S., Broeks, A., Rutgers, E. J., Smit, V. T. H. B. M., Cornelisse, C. J., van Beek, M., Janssen-Heijnen, M. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3942 · Cited by 104
High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer
Nilsson, M. P., Hartman, L., Kristoffersson, U., Johannsson, O. T., Borg, Å., Henriksson, K., Lanke, E., Olsson, H., & Loman, N. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3115-3 · Cited by 56
Metadata
- Authors
- Pierce, L. J., Phillips, K.-A., Griffith, K. A., Buys, S., Gaffney, D. K., Moran, M. S., Haffty, B. G., Ben-David, M., Kaufman, B., Garber, J. E., Merajver, S. D., Balmaña, J., Meirovitz, A., & Domchek, S. M.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2010-04-22
- Volume
- 121
- Issue
- 2
- Pages
- 389-398
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2073129224
- Cited by
- 199
- References
- 7
- FWCI
- 7.54
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. https://app.cochat.ai/papers/10.1007/s10549-010-0894-z
- The paper
- Pierce, L. J., Phillips, K.-A., Griffith, K. A., Buys, S., Gaffney, D. K., Moran, M. S., Haffty, B. G., Ben-David, M., Kaufman, B., Garber, J. E., Merajver, S. D., Balmaña, J., Meirovitz, A., & Domchek, S. M. (2010). Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-010-0894-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.